Literature DB >> 19153601

Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF.

Deo Prakash Pandey1, Rosamaria Lappano, Lidia Albanito, Antonio Madeo, Marcello Maggiolini, Didier Picard.   

Abstract

The steroid hormone oestrogen can signal through several receptors and pathways. Although the transcriptional responses mediated by the nuclear oestrogen receptors (ER) have been extensively characterized, the changes in gene expression elicited by signalling through the membrane-associated ER GPR30 have not been studied. We show here for ER-negative human breast cancer cells that the activation of GPR30 signalling by oestrogen or by hydroxytamoxifen (OHT), an ER antagonist but GPR30 agonist, induces a transcription factor network, which resembles that induced by serum in fibroblasts. The most strongly induced gene, CTGF, appears to be a target of these transcription factors. We found that the secreted factor connective tissue growth factor (CTGF) not only contributes to promote proliferation but also mediates the GPR30-induced stimulation of cell migration. These results provide a framework for understanding the physiological and pathological functions of GPR30. As the activation of GPR30 by OHT also induces CTGF in fibroblasts from breast tumour biopsies, these pathways may be involved in promoting aggressive behaviour of breast tumours in response to endogenous oestrogens or to OHT being used for endocrine therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19153601      PMCID: PMC2657575          DOI: 10.1038/emboj.2008.304

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  60 in total

1.  The transcriptional program in the response of human fibroblasts to serum.

Authors:  V R Iyer; M B Eisen; D T Ross; G Schuler; T Moore; J C Lee; J M Trent; L M Staudt; J Hudson; M S Boguski; D Lashkari; D Shalon; D Botstein; P O Brown
Journal:  Science       Date:  1999-01-01       Impact factor: 47.728

2.  Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.

Authors:  Isao Inoki; Takayuki Shiomi; Gakuji Hashimoto; Hiroyuki Enomoto; Hiroyuki Nakamura; Ken-ichi Makino; Eiji Ikeda; Shigeo Takata; Ken-ichi Kobayashi; Yasunori Okada
Journal:  FASEB J       Date:  2001-12-14       Impact factor: 5.191

3.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.

Authors:  E J Filardo; J A Quinn; K I Bland; A R Frackelton
Journal:  Mol Endocrinol       Date:  2000-10

4.  Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7.

Authors:  K Hishikawa; B S Oemar; F C Tanner; T Nakaki; T F Lüscher; T Fujii
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

Review 5.  Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor.

Authors:  Edward J Filardo; Jeffrey A Quinn; Edmond Sabo
Journal:  Steroids       Date:  2008-01-03       Impact factor: 2.668

Review 6.  Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein.

Authors:  Patricia de Winter; Patricia Leoni; David Abraham
Journal:  Growth Factors       Date:  2008-04       Impact factor: 2.511

7.  Expression of connective tissue growth factor (CTGF/CCN2) in head and neck squamous cell carcinoma.

Authors:  T C Mullis; X Tang; K T Chong
Journal:  J Clin Pathol       Date:  2008-05       Impact factor: 3.411

8.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

9.  The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation.

Authors:  Jian Teng; Zun-Yi Wang; Eric R Prossnitz; Dale E Bjorling
Journal:  Endocrinology       Date:  2008-05-08       Impact factor: 4.736

10.  GPR30 estrogen receptor agonists induce mechanical hyperalgesia in the rat.

Authors:  Julia Kuhn; Olayinka A Dina; Chandan Goswami; Vanessa Suckow; Jon D Levine; Tim Hucho
Journal:  Eur J Neurosci       Date:  2008-03-26       Impact factor: 3.386

View more
  128 in total

Review 1.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

2.  Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression.

Authors:  Natasha C Lucki; Marion B Sewer
Journal:  J Biol Chem       Date:  2011-04-14       Impact factor: 5.157

Review 3.  What have we learned about GPER function in physiology and disease from knockout mice?

Authors:  Eric R Prossnitz; Helen J Hathaway
Journal:  J Steroid Biochem Mol Biol       Date:  2015-07-16       Impact factor: 4.292

4.  The novel estrogen receptor GPER regulates the migration and invasion of ovarian cancer cells.

Authors:  Yan Yan; Huidi Liu; Haixia Wen; Xueli Jiang; Xuefeng Cao; Guangmei Zhang; Guoyi Liu
Journal:  Mol Cell Biochem       Date:  2013-04-12       Impact factor: 3.396

5.  The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Authors:  Eric A Ariazi; Eugen Brailoiu; Smitha Yerrum; Heather A Shupp; Michael J Slifker; Heather E Cunliffe; Michael A Black; Anne L Donato; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz; Nae J Dun; V Craig Jordan
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

Review 6.  Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER.

Authors:  Eric R Prossnitz; Matthias Barton
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-05-13       Impact factor: 3.072

Review 7.  Macromolecular Modelling and Docking Simulations for the Discovery of Selective GPER Ligands.

Authors:  Camillo Rosano; Marco Ponassi; Maria Francesca Santolla; Assunta Pisano; Lamberto Felli; Adele Vivacqua; Marcello Maggiolini; Rosamaria Lappano
Journal:  AAPS J       Date:  2015-11-16       Impact factor: 4.009

8.  Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.

Authors:  Q K Y Chan; H-M Lam; C-F Ng; A Y Y Lee; E S Y Chan; H-K Ng; S-M Ho; K-M Lau
Journal:  Cell Death Differ       Date:  2010-03-05       Impact factor: 15.828

9.  In vivo effects of a GPR30 antagonist.

Authors:  Megan K Dennis; Ritwik Burai; Chinnasamy Ramesh; Whitney K Petrie; Sara N Alcon; Tapan K Nayak; Cristian G Bologa; Andrei Leitao; Eugen Brailoiu; Elena Deliu; Nae J Dun; Larry A Sklar; Helen J Hathaway; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz
Journal:  Nat Chem Biol       Date:  2009-06       Impact factor: 15.040

10.  The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells.

Authors:  Jun Wan; Jinben Ma; Ju Mei; Genfa Shan
Journal:  J Exp Clin Cancer Res       Date:  2009-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.